Frontlight ResearchEarly access
CompletedNo phase
Efficacy and Safety of the New Defocus Spectacle Lens in Preventing Progression of Myopia
Key facts
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 174 people enrolled
- Started
- 23 Mar 2023
- Ended
- 22 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- New defocus spectacle lenses
- Convenional aspheric single-vision spectacle lenses
- Record updated
- 23 January 2025
Who can take part
- Age
- 6 years to 14 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 6 to 14 years
- Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -1.00 to -3.50 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.00 D
- Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
- The intraocular pressure of 10 to 21mmHg
- Volunteer to participate in this clinical trial with signature of the informed consent form
Who cannot take part
- Participation of the drug clinical trial within three month and the device clinical trial within one month
- Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursing products), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
- History of eye injury or intraocular surgery
- Ocular disease, such as uveitis and other inflammatory diseases, glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
- Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
- Clinically abnormal slit-lamp findings
- Abnormal fundus examination
- Only one eye meets the inclusion criteria
- Unable to have regular follow-up
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The clinical effects of new technical spectacles with refractive correction function are mixed. A randomised trial is designed to compare the effects of new defocusing spectacle lenses and traditional aspheric spectacle lenses on myopia progression in Chinese children aged 6-14 years.
The 2 groups in the trial
- New defocus spectacle lensTreatment being tested
The children in the experimental group will wear new defocus spectacle lens and receive follow-up examinations every half year.
Treatment: New defocus spectacle lenses
- Conventional aspheric single-vision spectacle lensesExisting treatment, for comparison
The children in the control group will wear conventional aspheric single-vision spectacles and receive follow-up examinations every half year.
Treatment: Convenional aspheric single-vision spectacle lenses
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of New Defocus Spectacle Lens in Preventing Progression of Myopia Compared With the Conventional Single-vision Spectacle Lens: a Randomized Controlled Trial Among Chinese Children
- Record updated
- 23 January 2025